BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19651365)

  • 1. High-risk HPV detection and concurrent HPV 16 and 18 typing with Abbott RealTime High Risk HPV test.
    Tang N; Huang S; Erickson B; Mak WB; Salituro J; Robinson J; Abravaya K
    J Clin Virol; 2009 Jul; 45 Suppl 1():S25-8. PubMed ID: 19651365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
    J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Abbott RealTime High Risk HPV and Hybrid Capture 2 for the detection of high-risk HPV DNA in a referral population setting.
    Venturoli S; Leo E; Nocera M; Barbieri D; Cricca M; Costa S; Santini D; Zerbini M
    J Clin Virol; 2012 Feb; 53(2):121-4. PubMed ID: 22115872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test.
    Poljak M; Kovanda A; Kocjan BJ; Seme K; Jancar N; Vrtacnik-Bokal E
    Acta Dermatovenerol Alp Pannonica Adriat; 2009 Sep; 18(3):94-103. PubMed ID: 19784522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology.
    Einstein MH; Martens MG; Garcia FA; Ferris DG; Mitchell AL; Day SP; Olson MC
    Gynecol Oncol; 2010 Aug; 118(2):116-22. PubMed ID: 20488510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology.
    Huang S; Erickson B; Tang N; Mak WB; Salituro J; Robinson J; Abravaya K
    J Clin Virol; 2009 Jul; 45 Suppl 1():S19-23. PubMed ID: 19651364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a new multiplex real-time polymerase chain reaction assay for the detection of human papillomavirus infections in a referral population.
    Jentschke M; Soergel P; Lange V; Kocjan B; Doerk T; Luyten A; Petry KU; Poljak M; Hillemanns P
    Int J Gynecol Cancer; 2012 Jul; 22(6):1050-6. PubMed ID: 22740006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the clinical performances of the AdvanSure HPV Screening Real-Time PCR, the Abbott Real-Time High-Risk HPV Test, and the Hybrid Capture High-Risk HPV DNA Test for Cervical Cancer Screening.
    Chung HS; Hahm C; Lee M
    J Virol Methods; 2014 Sep; 205():57-60. PubMed ID: 24814874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and genotyping of high risk human papillomavirus in cervical cancer samples from Punjab, Pakistan.
    Siddiqa A; Zainab M; Qadri I; Bhatti MF; Parish JL
    Viruses; 2014 Jul; 6(7):2762-77. PubMed ID: 25036463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study.
    Stoler MH; Wright TC; Sharma A; Apple R; Gutekunst K; Wright TL;
    Am J Clin Pathol; 2011 Mar; 135(3):468-75. PubMed ID: 21350104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between the Abbott RealTime High Risk HPV assay and the Hybrid Capture 2 assay for detecting high-risk human papillomavirus DNA in cervical specimens.
    Kaliterna V; Židovec Lepej S; Vince A
    J Med Microbiol; 2009 Dec; 58(Pt 12):1662-1663. PubMed ID: 19661205
    [No Abstract]   [Full Text] [Related]  

  • 12. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Abbott RealTime High Risk HPV test in evaluation of atypical squamous cells of undetermined significance from an Asian screening population.
    Wong OG; Lo CK; Szeto E; Cheung AN
    J Clin Virol; 2011 Jun; 51(2):136-8. PubMed ID: 21530385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Abbott RealTime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: a review of validation studies.
    Poljak M; Oštrbenk A
    Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(2):43-7. PubMed ID: 23836358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus detection using the Abbott RealTime high-risk HPV tests compared with conventional nested PCR coupled to high-throughput sequencing of amplification products in cervical smear specimens from a Gabonese female population.
    Moussavou-Boundzanga P; Koumakpayi IH; Labouba I; Leroy EM; Belembaogo E; Berthet N
    Virol J; 2017 Dec; 14(1):241. PubMed ID: 29268766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand.
    Simonella LM; Lewis H; Smith M; Neal H; Bromhead C; Canfell K
    BMC Infect Dis; 2013 Mar; 13():114. PubMed ID: 23452957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus-Based Screening in Mexico.
    Torres-Ibarra L; Cuzick J; Lorincz AT; Spiegelman D; Lazcano-Ponce E; Franco EL; Moscicki AB; Mahmud SM; Wheeler CM; Rivera-Paredez B; Hernández-López R; León-Maldonado L; Salmerón J;
    JAMA Netw Open; 2019 Nov; 2(11):e1915781. PubMed ID: 31747033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the analytical and clinical performances of Abbott RealTime High Risk HPV, Hybrid Capture 2, and DNA Chip assays in gynecology patients.
    Park S; Kang Y; Kim DG; Kim EC; Park SS; Seong MW
    Diagn Microbiol Infect Dis; 2013 Aug; 76(4):432-6. PubMed ID: 23791386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invader human papillomavirus (HPV) type 16 and 18 assays as adjuncts to HPV screening of cervical papanicolaou smears with atypical squamous cells of undetermined significance.
    Wong AK; Chan RC; Nichols WS; Bose S
    Cancer; 2009 Feb; 115(4):823-32. PubMed ID: 19127558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid-based cytology--new possibilities in the diagnosis of cervical lesions.
    Juric D; Mahovlić V; Rajhvajn S; Ovanin-Rakić A; Skopljanac-Macina L; Barisić A; Projić IS; Babić D; Susa M; Corusić A; Oresković S
    Coll Antropol; 2010 Mar; 34(1):19-24. PubMed ID: 20432728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.